NBPF1 (Neuroblastoma BreakPoint Family member 1) is a primate-specific gene with context-dependent tumor regulatory functions. Molecularly, NBPF1 acts primarily as a tumor suppressor through protein binding interactions 1 that inhibit key oncogenic signaling cascades. In cervical cancer, NBPF1 overexpression suppresses cell invasion and promotes apoptosis by inhibiting the PI3K/mTOR pathway 1. Similarly, in cutaneous squamous cell carcinoma, NBPF1 upregulation arrests cells in G1 phase and induces apoptosis via inhibition of the Akt-p53-Cyclin D pathway 2. During normal development, transient NBPF1 expression in the developing human hippocampus (gestational weeks 16-27) markedly increases PROX1+ cells, suggesting roles in neural progenitor differentiation 3. In neuroblastoma specifically, NBPF1 loss through 1p36 deletion or chr1 disruption correlates with tumor aggressiveness and serves as an independent prognostic biomarker for risk stratification 4 5. However, NBPF1 demonstrates oncogenic properties in liver cancer, where it promotes colony formation and invasion 6. This dual role extends to adrenocortical carcinoma, where NBPF1 correlates with immune hyporesponsiveness and poor prognosis 6. NBPF1 represents a context-specific therapeutic target with prognostic utility across multiple malignancies.